Remepy Raises $36M for Therapeutic Software

The line between biotech and health software is getting blurrier.

What happened

Remepy raised a $36M Series A. The company pairs prescription medicines with therapeutic software, aiming to create treatment approaches that combine drugs with digital interventions.

That puts Remepy in a hybrid category: not pure digital health, not traditional biotech, but a medicine-plus-software model.

Why it matters

Healthcare software is often focused on admin, scheduling or remote monitoring. Remepy’s angle is closer to the therapeutic layer, where software may be part of the treatment itself.

If the model works, it could create new ways to support drug efficacy, adherence, patient engagement and clinical follow-up.

The bigger picture

Digital therapeutics had a difficult first wave, but the broader idea has not disappeared. The next version may be more tightly linked to prescription medicine and clinical pathways rather than standalone wellness apps.